Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 2113-2127
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113
Table 2 Response to medical treatment and outcome of 75 patients with autoimmune liver diseases
Variables
All patients, n = 75
AIH, n = 54
ASC, n = 21
P value
Treatment, n
Prednisone alone26 (35%)19 (35%)7 (33%)1
Prednisone + Azathioprine30 (40%)28 (52%)2 (10%)< 0.001
Prednisone + MMF5 (7%)3 (5%)2 (10%)0.615
Prednisone + Vancomycin4 (5%)1 (2%)3 (14%)0.064
Prednisone + Azathioprine + Vancomycin 2 (3%)0 (0%)2 (10%)0.075
Prednisone + MMF + Vancomycin6 (8%)1 (2%)5 (23%)0.005
Prednisone + Tacrolimus1 (1%)1 (2%)0NA
Cyclosporine1 (1%)1 (2%)0NA
Response to treatment
Normal AST (NV ≤ 45 U/L): n69 (92%)52 (96%)17 (81%)0.048
Time to normalize AST (yr)0.1 (0.1-0.5)0.2 (0.1-0.6)0.1 (0.1-0.2)0.19
GGT (< 50 UI/L), n68 (91%)51 (94%)17 (81%)0.811
Time to normalize GGT (yr)0.3 (0.2-0.6)0.3 (0.2-0.5)0.3 (0.2-1.1)0.062
Immunological remission1: n25 (33%)22 (40%)3 (14%)0.032
Time to immunological remission3.1 (2.2-4.2)3.8 (2.9-4.3)3.4 (3.2-3.7)0.86
Relapse of AILD during treatment, n
At least one relapse36 (48%)22 (41%)14 (67%)< 0.070
1 relapse alone26 (35%)17 (31%)9 (43%)0.421
≥ 2 relapses10 (13%)5 (9%)5 (24%)0.131
Outcome at last follow up
Median follow up, yr (range)4.4 (0.6-13.8)4.1 (1.2-11.7)4.5 (0.6-13.8)0.079
Alive75 (100%)54 (100%)21 (100%)NA
OFF-IS therapy6 (8%)5 (9%)1 (5%)0.666
Medical treatment68 (91%)49 (91%)19 (90%)1
Liver transplant1 (1%)0 (0%)1 (5%)0.28